Companion Diagnostics Markets (A Realistic Assessment of the Opportunities, Challenges, Key Players and Important Trends in Personalized Medicine)

• Background
  
  
  
  
  
  • Potential Benefits of Companion Diagnostics
    
    
  • Pitfalls of Personalized Medicine
    
    
  • Scope and Methodology
    
    
  • Market Factors and Estimates
    
    
  • Drivers For Companion Diagnostics
    
    
  • Assumptions
    
    
  • Important Trends
    
    
  • Possible Tactic: Royalty Model

CHAPTER TWO: OVERVIEW OF COMPANION DIAGNOSTICS

• Personalized Medicine
  
  
• Potential Benefits
  
  
• Privacy and Public Perception
  
  
• Biomarkers and Companion Diagnostics
  
  
  
  
  
  • Types of Biomarkers

CHAPTER THREE: APPLICATIONS OF COMPANION DIAGNOSTICS

• Pharmacogenetics and Pharmacogenomics
  
  
• Historical Basis
  
  
• Current Techniques
  
  
• Requirements
  
  
• Cost-effectiveness
  
  
• Applications
  
  
  
  
  
  • The Cytochrome System
    
    
  • Cancer
    
    
  • Amgen
    
    
  • UAMS Multiple Myeloma Project
    
    
  • DakoAssay for TOP2A
    
    
  • GE and Eli Lilly
    
    
  • Epigenomics and Abbott
    
    
  • Celera and Merk
    
    
  • bioMerieiux and Ipsen
    
    
  • Acute Lymphoblastic Leukemia
  
  
  
• Regulatory Agencies
  
  
• Applications of Genome More Challenging Than Expected
  
  
• Cardiovascular Disease
  
  
• RAS polymorphisms With Drug Effectiveness
  
  
  
  
  
  • Pgp
    
    
  • Thiazide diuretics
    
    
  • 825T allele
    
    
  • HIT
    
    
  • Statins
  
  
  
• Psychiatry and Pharmacogenetics/Pharmacogenomics
  
  
• Is Herceptin a Paradigm?
  
  
• A Balancing Act Between the Players

CHAPTER FOUR: MAJOR WORLD MARKET FACTORS AND DATA FOR COMPANION DIAGNOSTICS

• Estimating Market Potential
  
  
• Associated Testing
  
  
• The Needs of Pharma and of Diagnostic Companies
  
  
• Questions Determining Companion Diagnostics Growth
  
  
• A Partial Change in Attitude
  
  
• Intellectual Property
  
  
• Cancer Market Potential Estimate
  
  
• Ideal Market Potential - Cancer, Heart Disease, Psychiatric
  
  
• Source: Kalorama Information
  
  
• Challenges Unique to Companion Diagnostics
  
  
• Privacy Concerns
  
  
• Fear of Learning About Diseases
  
  
• Use of Remnant Samples
  
  
• Avoiding Pitfalls of Market Calculation
  
  
• Companion Diagnostics Not Linked to Molecular Diagnostics
  
  
• Demonic and SNP Analysis
  
  
• Considering Time of Cooperative Development
  
  
• Market Realities to Consider
  
  
• Possible Tactic: Royalty Model

CHAPTER FIVE: COMPANY SUMMARIES

• Overview
  
  
• Abbott (Molecular) Diagnostics Subsidiary of Abbott Laboratories
  
  
• Affymetrix, Inc.
  
  
• Agilent Technologies, Inc
  
  
• Althea Technologies, Inc.
  
  
• Curidium Medica plc
  
  
• Dako
  
  
• Gen Probe
  
  
• Genzyme Corporation
  
  
• Ipsogen SAS
  
  
• Lipomics Technologies, Inc.
  
  
• Osmetech plc
  
  
• Perlegen Sciences
  
  
• Provista Life Sciences
  
  
• Qiagen NV
  
  
• Singulex, Inc.
  
  
• Theranostics Health
  
  
• Ventana Medical Systems

CHAPTER SIX: CONCLUSIONS AND STATEGIC IMPLICATIONS

• First Conclusion
  
  
• Implications:
  
  
• Second Conclusion
  
  
• Implications:
  
  
• Third Conclusion
  
  
• Implications:
  
  
• Fourth Conclusion
  
  
• Implications:
  
  
• Fifth Conclusion
  
  
• Implications:
  
  
• Sixth Conclusion
  
  
• Implications: Seventh Conclusion Implications:
  
  
• Eighth Conclusion
  
  
• Implications:
  
  
• Ninth Conclusion
  
  
• Implications:
  
  
• Tenth Conclusion
  
  
• Implications:

APPENDIX: GLOSSARY OF TERMS AND ABBREVIATIONS

CHAPTER ONE: EXECUTIVE SUMMARY

• 
  
  

  Table 1-1: Market Projections for Companion Diagnostics* in the United States: 2008 - 2018
  
  

  
  
  
• 
  
  

  Figure 1-1: Market Projection Trends for Companion Diagnostics in the United States: 2008 - 2018

CHAPTER THREE: APPLICATIONS OF COMPANION DIAGNOSTICS

• 
  
  

  Table 3-1 Companion Diagnostics Groups
  
  

  
  
  
• 
  
  

  Table 3-3: Frequency of Recessive Traits
  
  

  
  
  
• 
  
  

  Table 3-4: Existing Cancer Drugs Complimentary to Companion Diagnostics
  
  

  
  
  
• 
  
  

  Table 3-5: Recent Activities in Companion Diagnostics

CHAPTER FOUR: MAJOR WORLD MARKET FACTORS AND DATA FOR COMPANION DIAGNOSTICS

• 
  
  

  Table 4-1: The Ideal Potential Companion Diagnostics Markets for Cancer Therapeutics: 2008
  
  

  
  
  
• 
  
  

  Figure 4-1: The Ideal Potential Companion Diagnostics Markets for Cancer Therapeutics: 2008
  
  

  
  
  
• 
  
  

  Table 4-2: The Ideal Potential Companion Diagnostics Markets for Therapeutics Addressing the Top Four, High-Profile Cancers: 2008
  
  

  
  
  
• 
  
  

  Figure 4-2: The Ideal Potential Companion Diagnostics Markets for Therapeutics Addressing the Top Four, High-Profile Cancers: 2008
  
  

  
  
  
• 
  
  

  Figure 4-3: The Ideal Companion Diagnostics Market (Ideal vs. Likely to Benefit)
  
  

  
  
  
• 
  
  

  Figure 4-4 Subset of Ideal Market Likely to Benefit From Pharmaceutical Intervention (Likely to Benfit vs. Realistic Market)
  
  

  
  
  
• 
  
  

  Table 4-3: Market Projections for Companion Diagnostics* in the United States: 2008 - 2018
  
  

  
  
  
• 
  
  

  Figure 4-1: Market Projection Trends for Companion Diagnostics* in the United States: 2008 - 2018

CHAPTER SIX: CONCLUSIONS AND STATEGIC IMPLICATIONS

• Table 6-1: Hypothetical Cancer Therapy Outcome Based on Associated Genes